Diabetes and hypertension: Is there a common metabolic pathway?

Current Atherosclerosis Reports

Volumn 14, Issue 2, 2012, Pages 160-166

  Cheung, Bernard M Y ^a,b   Li, Chao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Diabetes; Hypertension; Insulin resistance; Metabolic pathway; Metabolic syndrome; Obesity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; FTO GENE; GENE; GENE CONVERSION; GENE IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GNDPA 2 GENE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MENTAL STRESS; METABOLIC SYNDROME X; MOLECULAR MODEL; OBESITY; OXIDATIVE STRESS; PHYSICAL ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPATHETIC NERVE; VASCULITIS;

DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLIC SYNDROME X; MOTOR ACTIVITY; OBESITY; OXIDATIVE STRESS; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; STRESS, PSYCHOLOGICAL;

EID: 84862825466     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0227-2     Document Type: Review

References (114)

1. Cheung BM. The hypertension-diabetes continuum. J Cardiovasc Pharmacol. 2010; 55: 333-9. This is a brief review of the overlap between hypertension and type 2 diabetes that proposes there is a spectrum ranging from hypertension without dysglycemia to type 2 diabetes without elevated blood pressure.
2. Landsberg L,MolitchM. Diabetes and hypertension: pathogenesis, prevention and treatment. Clin Exp Hypertens. 2004;26:621-8. (Pubitemid 40129750)
3. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000; 342:905-12. (Pubitemid 30177050)
4. Cheung BM, Wat NM, Tso AW, et al. Association between raised blood pressure and dysglycemia in Hong Kong Chinese. Diabetes Care. 2008;31:1889-91.
5. Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genomewide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008; 40:638-45. (Pubitemid 351601209)
6. Sober S, Org E, Kepp K, et al. Targeting 160 candidate genes for blood pressure regulation with a genome-wide genotyping array. PLoS One. 2009;4:e6034.
7. Ong KL, Tso AW, Leung RY, et al. A genetic variant in the gene encoding adrenomedullin predicts the development of dysglycemia over 6.4 years in Chinese. Clin Chim Acta. 2011;412:353-7.
8. Ong KL, Jiang CQ, Liu B, et al. Association of a genetic variant in the apolipoprotein A5 gene with the metabolic syndrome in Chinese. Clin Endocrinol (Oxf). 2011;74:206-13.
9. Cheung CY, Tso AW, Cheung BM, et al. Genetic variants associated with persistent central obesity and the metabolic syndrome in a 12-year longitudinal study. Eur J Endocrinol. 2011;164:381-8.
10. Ong KL, Li M, Tso AW, et al. Association of genetic variants in the adiponectin gene with adiponectin level and hypertension in Hong Kong Chinese. Eur J Endocrinol. 2010;163:251-7.
11. Ong KL, Leung RY, Wong LY, et al. Association of a polymorphism in the lipin 1 gene with systolic blood pressure in men. Am J Hypertens. 2008;21:539-45. (Pubitemid 351589675)
12. Ong KL, Wong LY, Man YB, et al. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides. 2006;27: 1659-67. (Pubitemid 43884768)
13. Chow WS, Cheung BM, Tso AW, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension. 2007;49:1455-61. (Pubitemid 46809394)
14. Tso AW, Sham PC, Wat NM, et al. Polymorphisms of the gene encoding adiponectin and glycaemic outcome of Chinese subjects with impaired glucose tolerance: a 5-year follow-up study. Diabetologia. 2006;49:1806-15. (Pubitemid 44025035)
15. Ng MC, So WY, Lam VK, et al. Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21- q25. Diabetes. 2004;53:2676-83. (Pubitemid 39299278)
16. Ng MC, So WY, Cox NJ, et al. Genome-wide scan for type 2 diabetes loci in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes. 2004;53:1609-13. (Pubitemid 38697677)
17. Ross KA. Evidence for somatic gene conversion and deletion in bipolar disorder, Crohn's disease, coronary artery disease, hypertension, rheumatoid arthritis, type-1 diabetes, and type-2 diabetes. BMC Med. 2011; 9: 12. This article showed that somatic gene conversion could be a significant causative factor in seven diseases, including hypertension, type 1 diabetes, and type 2 diabetes. There are some common SNPs identified in some of the seven diseases.
18. Moore TR. Fetal exposure to gestational diabetes contributes to subsequent adult metabolic syndrome. Am J Obstet Gynecol. 2010;202:643-9.
19. Xita N, Tsatsoulis A. Fetal origins of the metabolic syndrome. Ann N YAcad Sci. 2010; 1205: 148-55. This article argued that consequences of fetal adaptive responses might be evident later in life rather than at birth. Risk factors in pregnancy might predispose the fetus to hypertension, diabetes, or the metabolic syndrome in adulthood.
20. Guerrero-Romero F, Aradillas-Garcia C, Simental-Mendia LE, et al. Birth weight, family history of diabetes, and metabolic syndrome in children and adolescents. J Pediatr. 2010;156:719-23, 723 e1.
21. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286:H1597-1602. (Pubitemid 38525443)
22. Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol. 2004;286:R803- 813. (Pubitemid 38506821)
23. He YH, Jiang GX, Yang Y, et al. Obesity and its associations with hypertension and type 2 diabetes among Chinese adults age 40 years and over. Nutrition. 2009; 25: 1143-9. This was a crosssectional study of over 5000 people in the community in Shanghai showing that obesity was associated with a higher risk of both hypertension and type 2 diabetes.
24. Loos RJ, Bouchard C. Obesity-is it a genetic disorder? J Intern Med. 2003;254:401-25.
25. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet. 1997;27:325-51. (Pubitemid 27415169)
26. Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. J Hered. 1950;41:317-8.
27. Saunders CL, Chiodini BD, Sham P, et al. Meta-analysis of genome-wide linkage studies in BMI and obesity. Obesity (Silver Spring). 2007;15:2263-75. (Pubitemid 350004094)
28. Wang K, Li WD, Zhang CK, et al. A genome-wide association study on obesity and obesity-related traits. PLoS One. 2011;6: e18939.
29. Cheung CY, Tso AW, Cheung BM, et al. Obesity susceptibility genetic variants identified from recent genome-wide association studies: implications in a chinese population. J Clin Endocrinol Metab. 2010;95:1395-403.
30. Wang T, Huang Y, Xiao XH, et al. The association between common genetic variation in the FTO gene and metabolic syndrome in Han Chinese. Chin Med J (Engl). 2010;123:1852-8.
31. Wing MR, Ziegler JM, Langefeld CD, et al. Analysis of FTO gene variants with obesity and glucose homeostasis measures in the multiethnic Insulin Resistance Atherosclerosis Study cohort. Int J Obes (Lond). 2010.
32. Ng MC, Tam CH, So WY, et al. Implication of genetic variants near NEGR1, SEC16B, TMEM18, ETV5/DGKG, GNPDA2, LIN7C/BDNF, MTCH2, BCDIN3D/FAIM2, SH2B1, FTO, MC4R, and KCTD15 with obesity and type 2 diabetes in 7705 Chinese. J Clin Endocrinol Metab. 2010;95:2418-25.
33. Song Y, Altarejos J, Goodarzi MO, et al. CRTC3 links catecholamine signalling to energy balance. Nature. 2010;468:933-9.
34. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006;15:152-8.
35. Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51:1157-65. (Pubitemid 34438363)
36. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-26.
37. Tracy RP. Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging. Int J Obes Relat Metab Disord. 2003;27 Suppl 3:S29-34. (Pubitemid 38019185)
38. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl. 2003;134:10-17. (Pubitemid 36565031)
39. Karnoutsos K, Papastergiou P, Stefanidis S, et al. Periodontitis as a risk factor for cardiovascular disease: the role of antiphosphorylcholine and anti-cardiolipin antibodies. Hippokratia. 2008;12:144-9. (Pubitemid 351962098)
40. Persson GR, Persson RE. Cardiovascular disease and periodontitis: an update on the associations and risk. J Clin Periodontol. 2008;35:362-79.
41. Watanabe K, Petro BJ, Shlimon AE, et al. Effect of periodontitis on insulin resistance and the onset of type 2 diabetes mellitus in Zucker diabetic fatty rats. J Periodontol. 2008;79:1208-16.
42. Nesbitt MJ, Reynolds MA, Shiau H, et al. Association of periodontitis and metabolic syndrome in the Baltimore Longitudinal Study of Aging. Aging Clin Exp Res. 2010;22:238-42.
43. Tsioufis C, Kasiakogias A, Thomopoulos C, et al. Periodontitis and blood pressure: the concept of dental hypertension. Atherosclerosis. 2011;219:1-9.
44. Page RC. The pathobiology of periodontal diseases may affect systemic diseases: inversion of a paradigm. Ann Periodontol. 1998;3:108-20.
45. Hung HC, Willett W, Merchant A, et al. Oral health and peripheral arterial disease. Circulation. 2003;107:1152-7. (Pubitemid 36297207)
46. Blake GJ, Rifai N, Buring JE, et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993-9. (Pubitemid 37553568)
47. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763-71. (Pubitemid 34633846)
48. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-51. (Pubitemid 37505526)
49. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci. 2007;112:375-84. (Pubitemid 46587452)
50. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-8. (Pubitemid 24176909)
51. Yamakawa T, Tanaka S, Numaguchi K, et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension. 2000;35:313-8. (Pubitemid 30054192)
52. Taubman MB, Berk BC, Izumo S, et al. Angiotensin II induces cfos mRNA in aortic smooth muscle. Role of Ca2+ mobilization and protein kinase C activation. J Biol Chem. 1989;264:526-30. (Pubitemid 19027636)
53. Ushio-Fukai M, Alexander RW, Akers M, et al. p38 Mitogenactivated protein kinase is a critical component of the redoxsensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem. 1998;273:15022-9. (Pubitemid 28272796)
54. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensinconverting enzyme inhibition prevents arterial nuclear factorkappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532-41. (Pubitemid 27142812)
55. Schieffer B, Luchtefeld M, Braun S, et al. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res. 2000;87:1195-201.
56. Jesmin J, Rashid MS, Jamil H, et al. Gene regulatory network reveals oxidative stress as the underlying molecular mechanism of type 2 diabetes and hypertension. BMCMed Genomics. 2010;3:45.
57. Tsuchida A, Yamauchi T, Takekawa S, et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 2005;54:3358-70. (Pubitemid 43334324)
58. Chawla A, Barak Y, Nagy L, et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001;7:48-52. (Pubitemid 32095641)
59. Shah P, Mittal A, Bharatam PV. CoMFA analysis of dual/multiple PPAR activators. Eur J Med Chem. 2008;43:2784-91.
60. Madhavan GR, Chakrabarti R, Reddy KA, et al. Dual PPARalpha and -gamma activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential. Bioorg Med Chem. 2006;14:584-91. (Pubitemid 41767619)
61. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004;110:3687-92. (Pubitemid 39665258)
62. Koh KK, Son JW, Ahn JY, et al. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004;44:180-5. (Pubitemid 39014236)
63. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289:1799-804. (Pubitemid 37430249)
64. Witkowska AM. Soluble ICAM-1: a marker of vascular inflammation and lifestyle. Cytokine. 2005;31:127-34. (Pubitemid 40910228)
65. Sjogren P, Cederholm T, Heimburger M, et al. Simple advice on lifestyle habits and long-term changes in biomarkers of inflammation and vascular adhesion in healthy middle-aged men. Eur J Clin Nutr. 2010; 64: 1450-6. This article showed that even small efforts to improve diet and physical activity could influence biomarkers of inflammation. Such efforts may improve vascular function reducing the risk of diabetes and hypertension.
66. Yki-Järvinen H. Nonglycemic effects of insulin. Clin Cornerstone. 2003; Suppl 4: S6-12.
67. Jellinger PS. Metabolic consequences of hyperglycemia and insulin resistance. Clin Cornerstone. 2007;8 Suppl 7:S30-42. (Pubitemid 350301031)
68. Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating beta-blockers. J Clin Hypertens (Greenwich). 2011;13:52-9.
69. Stump CS, Clark SE, Sowers JR. Oxidative stress in insulinresistant conditions: cardiovascular implications. Treat Endocrinol. 2005;4:343-51. (Pubitemid 41751170)
70. Leiter LA, Lewanczuk RZ. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition. Am J Hypertens. 2005;18:121-8. (Pubitemid 40187358)
71. Sharma AM, Engeli S. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr. 2006;1:29-35.
72. Ceriello A. Oxidative stress and glycemic regulation. Metabolism. 2000;49:27-9. (Pubitemid 30091790)
73. Boden G, Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care. 2004;27:2253-9. (Pubitemid 39167198)
74. Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368:1-19. (Pubitemid 43776015)
75. Fonseca V, Desouza C, Asnani S, et al. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev. 2004;25:153-75. (Pubitemid 38269978)
76. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000;283:221-8. (Pubitemid 30039222)
77. Grundy SM, Brewer Jr HB, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-8. (Pubitemid 38133916)
78. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28. (Pubitemid 40523737)
79. Yeni-Komshian H, Carantoni M, Abbasi F, et al. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000;23:171-5. (Pubitemid 30071019)
80. Lillioja S, Mott DM, Zawadzki JK, et al. In vivo insulin action is familial characteristic in nondiabetic Pima-Indians. Diabetes. 1987;36:1329-35. (Pubitemid 17163996)
81. Zoratti R, Godsland IF, Chaturvedi N, et al. Relation of plasma lipids to insulin resistance, nonesterified fatty acid levels, and body fat in men from three ethnic groups: relevance to variation in risk of diabetes and coronary disease. Metabolism. 2000;49:245-52. (Pubitemid 30090892)
82. Reaven GM. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. J Clin Hypertens (Greenwich). 2011;13:238-43.
83. Morimoto K, Morikawa M, Kimura H, et al. Mental stress induces sustained elevation of blood pressure and lipid peroxidation in postmenopausal women. Life Sci. 2008;82:99-107. (Pubitemid 350251397)
84. Pickering TG. Mental stress as a causal factor in the development of hypertension and cardiovascular disease. Curr Hypertens Rep. 2001;3:249-54.
85. Esler M, Eikelis N, Schlaich M, et al. Chronic mental stress is a cause of essential hypertension: presence of biological markers of stress. Clin Exp Pharmacol Physiol. 2008;35:498-502. (Pubitemid 351326787)
86. Soucek M, Kara T. Stress-induced hypertension and diabetes mellitus. Vnitr Lek. 2001;47:315-9.
87. Seematter G, Guenat E, Schneiter P, et al. Effects of mental stress on insulin-mediated glucose metabolism and energy expenditure in lean and obese women. Am J Physiol Endocrinol Metab. 2000;279:E799-805.
88. Schnall PL, Pieper C, Schwartz JE, et al. The relationship between job strain, workplace diastolic blood-pressure, and leftventricular mass index - results of a case-control study. Jama-J Am Med Assoc. 1990;263:1929-35. (Pubitemid 20134768)
89. Jonas BS, Franks P, Ingram DD. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Fam Med. 1997;6:43-9.
90. Kario K, Ohashi T. After a major earthquake, stroke death occurs more frequently than coronary heart disease death in very old subjects. J Am Geriatr Soc. 1998;46:537-8.
91. Kario K, Ohashi T. Increased coronary heart disease mortality after the Hanshin-Awaji earthquake among the older community on Awaji Island. J Am Geriatr Soc. 1997;45:610-3. (Pubitemid 27213132)
92. Miller TQ, Smith TW, Turner CW, et al. A meta-analytic review of research on hostility and physical health. Psychol Bull. 1996;119:322-48.
93. Chapuis B, Vidal-Petiot E, Orea V, et al. Linear modelling analysis of baroreflex control of arterial pressure variability in rats. J Physiol. 2004;559:639-49. (Pubitemid 39263825)
94. Barrett CJ, Ramchandra R, Guild SJ, et al. What sets the longterm level of renal sympathetic nerve activity: a role for angiotensin II and baroreflexes? Circ Res. 2003;92:1330-6. (Pubitemid 36773475)
95. McDowall LM, Horiuchi J, Killinger S, et al. Modulation of the baroreceptor reflex by the dorsomedial hypothalamic nucleus and perifornical area. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1020-1026.
96. Julien C, Saul JP, Parati G. Very low frequency blood pressure fluctuations: not only myogenic responsiveness. J Hypertens. 2008;26:1065-8. (Pubitemid 351670495)
97. Kanbar R, Orea V, Chapuis B, et al. A transfer function method for the continuous assessment of baroreflex control of renal sympathetic nerve activity in rats. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1938-1946. (Pubitemid 350085669)
98. Bachen EA, Muldoon MF, Matthews KA, et al. Effects of hemoconcentration and sympathetic activation on serum lipid responses to brief mental stress. Psychosom Med. 2002;64:587-94. (Pubitemid 34791161)
99. Bjorntorp P. Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J Intern Med. 1991;230:195-201.
100. Pickering T. Cardiovascular pathways: socioeconomic status and stress effects on hypertension and cardiovascular function. Ann N Y Acad Sci. 1999;896:262-77. (Pubitemid 30040254)
101. Narkiewicz K. Obesity-related hypertension: relevance of vascular responses to mental stress. J Hypertens. 2002;20:1277-8. (Pubitemid 34925667)
102. Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int J Obes Relat Metab Disord. 2000;24 Suppl 2: S80-85. (Pubitemid 30461955)
103. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-44.
104. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulindependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia. 1991;34:891-8.
105. Laaksonen DE, Lindstrom J, Lakka TA, et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes. 2005;54:158-65. (Pubitemid 40105108)
106. Parker ED, Schmitz KH, Jacobs Jr DR, et al. Physical activity in young adults and incident hypertension over 15 years of followup: the CARDIA study. Am J Public Health. 2007;97:703-9. (Pubitemid 47280170)
107. Cederholm J, Wibell L. The relationship of blood pressure to blood glucose and physical leisure time activity. A study of hypertension in a survey of middle-aged subjects in Uppsala 1981-82. Acta Med Scand. 1986;219:37-46. (Pubitemid 16145153)
108. Scott RA, Bailey ME, Moran CN, et al. FTO genotype and adiposity in children: physical activity levels influence the effect of the risk genotype in adolescent males. Eur J Hum Genet. 2010; 18: 1339-43. This article reported that in the GENESIS study, FTO genotype was only related to obesity in physically inactive males, highlighting physical activity as an important factor modifying the effect of FTO genotype.
109. Lee HJ, Kim IK, Kang JH, et al. Effects of common FTO gene variants associated with BMI on dietary intake and physical activity in Koreans. Clin Chim Acta. 2010;411:1716-22.
110. Sonestedt E, Gullberg B, Ericson U, et al. Association between fat intake, physical activity and mortality depending on genetic variation in FTO. Int J Obes (Lond). 2011;35:1041-1049.
111. Ruiz JR, Labayen I, Ortega FB, et al. Attenuation of the effect of the FTO rs9939609 polymorphism on total and central body fat by physical activity in adolescents: the HELENA study. Arch Pediatr Adolesc Med. 2010;164:328-33.
112. Fossum E, Gleim GW, Kjeldsen SE, et al. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. Journal of Internal Medicine. 2007;262:439-48. (Pubitemid 47404363)
113. Mugo MN, Stump CS, Rao PG, et al. Hypertension and diabetes mellitus. In: Black HR, Elliott WJ, editors. Hypertension: A Companion to Braunwald's Heart Disease. Elsevier; 2007. p. 114.
114. Cheung BM. Drug treatment for obesity in the post-sibutramine era. Drug Saf. 2011;34:641-50.